Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Kylo-0603 in healthy subjects
NCT06365580Phase 1Completed
- Sponsor
- Kylonova Biopharma
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Kylo-0603 with Placebo (2 arms). Primary endpoint: Incidence of adverse events up to 3 weeks. Started May 2023; status: completed.
02
Drugs
kylo-0603
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06365580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365580.